An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Ipatasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Genentech
- 17 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 10 Mar 2014 Planned End Date changed from 1 Mar 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 29 Jul 2013 Planned end date changed from 1 Jan 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.